✦ LIBER ✦

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

✍ Scribed by Tanja Trarbach, Beate Schultheis, Thomas C. Gauler, Vesile Schneider, Dirk Strumberg, Wilfried E. E. Eberhardt, Stephanie Le Scouiller, Marcelo Marotti, Kathryn H. Brown, Joachim Drevs

Book ID: 118299053
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 379 KB
Volume: 30
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-011-9754-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1230 Cediranib (an oral, highly potent V

1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

✍ T. Trarbach; J. Drevs; D. Strumberg; T.C. Gauler; V. Schneider; W.E. Eberhardt; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Phase I evaluation of cediranib, a selec

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

✍ Hester van Cruijsen; Emile E. Voest; Cornelis J.A. Punt; Klaas Hoekman; Petronel 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 392 KB

Phase Ib/II, open-label, dose-escalation

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

✍ Kefford, Richard; Sullivan, Ryan J; Miller, Wilson H; Elez, Elena M; Tan, Daniel 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 91 KB

Phase I study of the multidrug resistanc

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

✍ Lyly H. Lê; Malcolm J. Moore; Lillian L. Siu; Amit M. Oza; Martha MacLean; Bryn 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 285 KB

Phase I clinical, pharmacokinetic and ph

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

✍ Razak, A R A; Hotte, S J; Siu, L L; Chen, E X; Hirte, H W; Powers, J; Walsh, W; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 308 KB

1246 POSTER A Phase I Dose-escalation St

1246 POSTER A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours

✍ G.S. Falchook; S. Fu; H.M. Amin; S.A. Piha-Paul; D.S. Hong; A. Naing; M.B. Kleve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB